Form 4: Avalon Ventures XI, L.P. Sells Janux Therapeutics Shares

Avalon Ventures XI, L.P. reports the sale of Janux Therapeutics, Inc. shares across multiple transactions on June 3, 2024.

Summary

• On June 3, 2024, Avalon Ventures XI, L.P. sold shares of Janux Therapeutics, Inc. common stock.
• A total of 677,279 shares were sold directly at a weighted average price of $54.75.
• Additionally, 131,196 shares held by Avalon BioVentures I, LP and 691,525 shares held by Avalon BioVentures SPV I, L.P. were sold at the same weighted average price.
• Following these transactions, Avalon Ventures XI, L.P. directly owns 3,271,216 shares, Avalon BioVentures I, LP owns 633,673 shares, and Avalon BioVentures SPV I, L.P. owns 3,340,018 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a report of stock sales, without explicit positive or negative implications. The impact depends on the market's interpretation of the sale.

Industry Context

This Form 4 filing indicates a significant transaction by a major shareholder, Avalon Ventures, which could influence investor sentiment and trading activity in Janux Therapeutics. Monitoring subsequent filings and market reactions will be important to assess the long-term impact.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders, as mandated by the SEC.
• The size of the transaction is significant and may be compared to similar sales by major shareholders in comparable biotech companies to gauge its relative impact.

Stakeholder Impact

• Shareholders may react to the news of a large shareholder selling a portion of their holdings.
• The market may interpret this sale as a signal about the company's future prospects.

Key Dates